FDA
approval
· 2022-09-02
FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
FDA has approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for KESIMPTA (OFATUMUMAB)